Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Anthony_Johnson
|
| gptkbp:closed |
2023
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
kidney disease
|
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:Jason_Meyenburg
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Goldfinch Bio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:specialty |
genomics
precision medicine |
| gptkbp:status |
defunct
|
| gptkbp:therapeuticArea |
chronic kidney disease
focal segmental glomerulosclerosis |
| gptkbp:website |
https://www.goldfinchbio.com
|
| gptkbp:bfsParent |
gptkb:Third_Rock_Ventures
|
| gptkbp:bfsLayer |
6
|